Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (SHG:600671) — Market Cap & Net Worth
Market Cap & Net Worth: Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671)
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (SHG:600671) has a market capitalization of $320.05 Million (CN¥2.19 Billion) as of June 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #14598 globally and #4355 in its home market, demonstrating a 10.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's stock price CN¥17.96 by its total outstanding shares 121778885 (121.78 Million). Review Hangzhou TianMuShan Pharmaceutical Enter balance sheet liabilities to assess the company's total debt and financial obligations.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Market Cap History: 2016 to 2026
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's market capitalization history from 2016 to 2026. Data shows change from $549.04 Million to $320.05 Million (-3.91% CAGR).
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.46x
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's market cap is 1.46 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.50x
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's market cap is 17.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $549.04 Million | $123.73 Million | $1.22 Million | 4.44x | 451.07x |
| 2017 | $450.31 Million | $176.38 Million | $8.14 Million | 2.55x | 55.31x |
| 2018 | $285.12 Million | $358.47 Million | -$9.88 Million | 0.80x | N/A |
| 2019 | $219.54 Million | $297.07 Million | $50.68 Million | 0.74x | 4.33x |
| 2020 | $153.43 Million | $206.63 Million | -$40.52 Million | 0.74x | N/A |
| 2021 | $160.02 Million | $147.07 Million | -$29.80 Million | 1.09x | N/A |
| 2022 | $169.47 Million | $108.91 Million | -$67.52 Million | 1.56x | N/A |
| 2023 | $207.78 Million | $121.78 Million | -$38.28 Million | 1.71x | N/A |
| 2024 | $156.46 Million | $217.30 Million | $15.25 Million | 0.72x | 10.26x |
| 2025 | $308.47 Million | $211.75 Million | $17.62 Million | 1.46x | 17.50x |
Competitor Companies of 600671 by Market Capitalization
Companies near Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd in the global market cap rankings as of June 22, 2026.
Key companies related to Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #27 globally with a market cap of $550.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1098.57 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #27 | Johnson & Johnson | NYSE:JNJ | $550.26 Billion | $228.39 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $216.49 |
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd's market cap moved from $549.04 Million to $ 320.05 Million, with a yearly change of -3.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥320.05 Million | +3.76% |
| 2025 | CN¥308.47 Million | +97.15% |
| 2024 | CN¥156.46 Million | -24.70% |
| 2023 | CN¥207.78 Million | +22.61% |
| 2022 | CN¥169.47 Million | +5.90% |
| 2021 | CN¥160.02 Million | +4.30% |
| 2020 | CN¥153.43 Million | -30.11% |
| 2019 | CN¥219.54 Million | -23.00% |
| 2018 | CN¥285.12 Million | -36.68% |
| 2017 | CN¥450.31 Million | -17.98% |
| 2016 | CN¥549.04 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 22nd, 2026 the market cap of Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $320.05 Million USD |
| MoneyControl | $320.05 Million USD |
| MarketWatch | $320.05 Million USD |
| marketcap.company | $320.05 Million USD |
| Reuters | $320.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces tablets, granules, pills, oral solutions, and other medications; and health food products, including oral liquids, syrups, eye drops, pills, soft capsules, tablets, and granules. It also sells prepared sl… Read more